RÉSUMÉ
Introducción: La Farmacia comunitaria vasca tiene una larga tradición de colaboración con la Dirección de Farmacia del Departamento de Salud del Gobier-no Vasco. En mayo de 2017 se firmó un Convenio de colaboración entre el Departamento de Salud y los tres colegios de farmacéuticos vascos para la puesta en marcha de un Programa piloto de Segui-miento Farmacoterapéutico Integral a pacientes crónicos polimedicados en el que el farmacéutico comunitario realizaría seguimiento farmacotera-péutico a pacientes con Diabetes tipo2. Método: Se realizó el servicio de seguimiento farmacoterapéutico en farmacias de tres organi-zaciones sanitarias integradas de Alava, Bizkaia y Gipuzkoa. Participaron 18 farmacias con 7 pacien-tes cada una. Criterios de inclusión: paciente con diabetes tipo2 que tomaban 8 o más principios activos de forma continuada. Durante los 12 meses de estudio se analizaron tres puntos: inicio (V1), 6 meses (V2) y al finalizar el estudio (V3).Resultados: De los 127 pacientes inicialmente previstos finalizaron el estudio 87. No se obtuvie-ron diferencias significativas en el valor de HbA1c entre inicio y final. Por el contrario, el número de problemas de salud no controlados disminuyó en un 47% (p=0,001) sin que se modificase el número de medicamentos. Los PRM más frecuentes en V3 fueron el conocimiento insuficiente del medicamen-to (34%) y la falta de adherencia (19%). Mejoraron tanto el conocimiento y la adherencia (p<0,001) como la calidad de vida (p<0,05). Conclusiones: Aunque el programa no ha tenido impacto en el valor de la HbA1c, sí ha contribuido a controlar otros problemas de salud, así como la adherencia, el conocimiento sobre los medicamen-tos y la calidad de vida de los pacientes. (AU)
Introduction: Basque community pharmacy has a long tradition of collaborating with Basque health authorities. In May 2017, a collaboration agreement was signed between the Department of Health and the three Basque Pharmaceutical Associations "for the implementation of a Pilot Program for Medi-cation review with follow up service for chronic polymedicated patients". Method: The medication review with follow up service was carried out in pharmacies of three integrated health organizations in Alava, Bizkaia and Gipuzkoa. 18 pharmacies participated with 7 patients each. Inclusion criteria: patients with type 2 diabetes who were taking 8 or more medicines. During the 12 months of the study, three points were analyzed: baseline (V1), 6 months (V2) and at the end of the study (V3).Results: Of the 127 initially planned patients, 87 completed the study. No significant differences were obtained in the HbA1c value between baseline and the end. In contrast, the number of uncontro-lled health problems decreased by 47% (p=0.001) without changing the number of medications. The most frequent DRPs in V3 were insufficient knowle-dge of the medication (34%) and lack of adherence (19%). Both, knowledge and adherence (p<0.001) and quality of life (p<0.05) improved.Conclusions: Although the program has not had an impact on the value of HbA1c, it has contributed to controlling other health problems, as well as adher-ence, knowledge about medications and the quality of life of patients. (AU)
Sujet(s)
Humains , Post-cure , Maladie chronique/traitement médicamenteux , Polypharmacie , Association de médicaments , Diabète de type 2/traitement médicamenteux , Diabète de type 2/thérapieRÉSUMÉ
BACKGROUND: Childrenâ ≤36 months with diffuse intrinsic pontine glioma (DIPG) have increased long-term survival (LTS, overall survival (OS)â ≥24 months). Understanding distinguishing characteristics in this population is critical to improving outcomes. METHODS: Patientsâ ≤36 months at diagnosis enrolled on the International DIPG Registry (IDIPGR) with central imaging confirmation were included. Presentation, clinical course, imaging, pathology and molecular findings were analyzed. RESULTS: Among 1183 patients in IDIPGR, 40 were eligible (median age: 29 months). Median OS was 15 months. Twelve patients (30%) were LTS, 3 (7.5%) very long-term survivorsâ ≥5 years. Among 8 untreated patients, median OS was 2 months. Patients enrolled in the registry but excluded from our study by central radiology review or tissue diagnosis had median OS of 7 months. All but 1 LTS received radiation. Among 32 treated patients, 1-, 2-, 3-, and 5-year OS rates were 68.8%, 31.2%, 15.6% and 12.5%, respectively. LTS had longer duration of presenting symptoms (Pâ =â .018). No imaging features were predictive of outcome. Tissue and genomic data were available in 18 (45%) and 10 patients, respectively. Among 9 with known H3K27M status, 6 had a mutation. CONCLUSIONS: Childrenâ ≤36 months demonstrated significantly more LTS, with an improved median OS of 15 months; 92% of LTS received radiation. Median OS in untreated children was 2 months, compared to 17 months for treated children. LTS had longer duration of symptoms. Excluded patients demonstrated a lower OS, contradicting the hypothesis that childrenâ ≤36 months with DIPG show improved outcomes due to misdiagnosis.
Sujet(s)
Astrocytome , Tumeurs du tronc cérébral , Gliome , Enfant d'âge préscolaire , Humains , Tumeurs du tronc cérébral/diagnostic , Tumeurs du tronc cérébral/génétique , Tumeurs du tronc cérébral/thérapie , Gliome/génétique , Gliome/thérapie , Gliome/anatomopathologie , EnregistrementsRÉSUMÉ
INTRODUCTION: Standards for chemotherapy against choroid plexus tumors (CPT) have not yet been established. METHODS: CPT-SIOP-2000 (NCT00500890) was an international registry for all CPT nesting a chemotherapy randomization for high-risk CPT with Carboplatin/Etoposide/Vincristine (CarbEV) versus Cyclophosphamide/Etoposide/Vincristine (CycEV). Patients older than three years were recommended to receive irradiation: focal fields for non-metastatic CPC, incompletely resected atypical choroid plexus papilloma (APP) or metastatic choroid plexus papilloma (CPP); craniospinal fields for metastatic CPC/APP and non-responsive CPC. High risk was defined as choroid plexus carcinoma (CPC), incompletely resected APP, and all metastatic CPT. From 2000 until 2010, 158 CPT patients from 23 countries were enrolled. RESULTS: For randomized CPC, the 5/10 year progression free survival (PFS) of patients on CarbEV (n = 20) were 62%/47%, respectively, compared to 27%/18%, on CycEV (n = 15), (intention-to-treat, HR 2.6, p = 0.032). Within the registry, histological grading was the most influential prognostic factor: for CPP (n = 55) the 5/10 year overall survival (OS) and the event free survival (EFS) probabilities were 100%/97% and 92%/92%, respectively; for APP (n = 49) 96%/96% and 76%/76%, respectively; and for CPC (n = 54) 65%/51% and 41%/39%, respectively. Without irradiation, 12 out of 33 patients with CPC younger than three years were alive for a median of 8.52 years. Extent of surgery and metastases were not independent prognosticators. CONCLUSIONS: Chemotherapy for Choroid Plexus Carcinoma is feasible and effective. CarbEV is superior to CycEV. A subset of CPC can be cured without irradiation.
Sujet(s)
Protocoles de polychimiothérapie antinéoplasique , Tumeurs du plexus choroïde , Essais contrôlés randomisés comme sujet , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Carcinomes/traitement médicamenteux , Tumeurs du plexus choroïde/traitement médicamenteux , Étoposide/usage thérapeutique , Humains , Enregistrements , Résultat thérapeutique , Vincristine/usage thérapeutiqueRÉSUMÉ
BACKGROUND: Diffuse intrinsic pontine glioma (DIPG) remains a clinico-radiologic diagnosis without routine tissue acquisition. Reliable imaging distinction between DIPG and other pontine tumors with potentially more favorable prognoses and treatment considerations is essential. METHODS: Cases submitted to the International DIPG registry (IDIPGR) with histopathologic and/or radiologic data were analyzed. Central imaging review was performed on diagnostic brain MRIs (if available) by two neuro-radiologists. Imaging features suggestive of alternative diagnoses included nonpontine origin, <50% pontine involvement, focally exophytic morphology, sharply defined margins, and/or marked diffusion restriction throughout. RESULTS: Among 286 patients with pathology from biopsy and/or autopsy, 23 (8%) had histologic diagnoses inconsistent with DIPG, most commonly nondiffuse low-grade gliomas and embryonal tumors. Among 569 patients with centrally-reviewed diagnostic MRIs, 40 (7%) were classified as non-DIPG, alternative diagnosis suspected. The combined analysis included 151 patients with both histopathology and centrally-reviewed MRI. Of 77 patients with imaging classified as characteristic of DIPG, 76 (99%) had histopathologic diagnoses consistent with DIPG (infiltrating grade II-IV gliomas). Of 57 patients classified as likely DIPG with some unusual imaging features, 55 (96%) had histopathologic diagnoses consistent with DIPG. Of 17 patients with imaging features suggestive of an alternative diagnosis, eight (47%) had histopathologic diagnoses inconsistent with DIPG (remaining patients were excluded due to nonpontine tumor origin). Association between central neuro-imaging review impression and histopathology was significant (p < 0.001), and central neuro-imaging impression was prognostic of overall survival. CONCLUSIONS: The accuracy and important role of central neuro-imaging review in confirming the diagnosis of DIPG is demonstrated.
Sujet(s)
Astrocytome , Tumeurs du tronc cérébral , Gliome , Humains , Tumeurs du tronc cérébral/anatomopathologie , Gliome/imagerie diagnostique , Gliome/anatomopathologie , EnregistrementsRÉSUMÉ
El glioma del nervio óptico es una entidad de muy baja incidencia en pacientes adultos, lo cual impide tener suficiente información sobre historia natural y conducta terapéutica en este grupo etario. En el presente artículo comunicamos el caso de un paciente de 27 años de edad con compromiso agudo del nervio óptico izquierdo debido a hemorragia intra tumoral, forma de presentación muy poco común en este tipo de tumores. Se realizó la resección mediante un abordaje endoscópico transesfenoidal extendido, con preservación funcional de la vía óptica contralateral. La anatomía patológica confirmó astrocitoma pilocítico positivo para el rearreglo KIAA 1549-BRAF. y negativo para la mutación BRAF V600E. Teniendo en cuenta la histopatología y biología molecular en este caso, la estabilidad visual contralateral y la resección quirúrgica amplia, se decidió no realizar tratamiento adyuvante con radioterapia o quimioterapia. El objetivo de esta conducta fue evitar lesiones adicionales sobre el quiasma, nervio óptico contralateral y/o hipotálamo. Dada la escasa información existente en la literatura médica, el reporte de este caso podría contribuir con información adicional en el manejo y conducta terapéutica de este tipo de lesiones.
The optic nerve glioma is a very uncommon entity in adult patients, with little information about its natural history and therapeutical management. We report the case of a 27-year-old patient with acute involvement of the left optic nerve due to intratumoral hemorrhage, a very uncommon form of presentation in this type of tumor. Resection was performed using an extended transsphenoidal endoscopic approach, with functional preservation of the contralateral optic pathway. The histopathology confirmed positive pilocytic astrocytoma with KIAA 1549-BRAF rearrangement and without BRAF V600E mutation. Considering the histopathology and molecular biology, the contralateral visual stability and the wide surgical resection, it was decided not to perform further treatment. The purpose of this decision was to avoid additional damage to the chiasm, contralateral optic nerve and/or hypothalamus. Given the limited data available in medical literature, the report of this case could contribute with additional information on the management and therapeutic approach of this type of tumors
Sujet(s)
Humains , Mâle , Gliome du nerf optique , Nerf optique , Endoscopie , HémorragieRÉSUMÉ
AIMS: von Hippel-Lindau (VHL) disease is caused by mutations in the VHL tumor suppressor gene. As tumors that develop in the context of VHL also occur in a sporadic context, the frequency of this syndrome may be underestimated. Our aim was to identify VHL gene mutations in Argentinian patients who fulfilled the clinical criteria for type 1 VHL disease and in patients with VHL-associated manifestations that did not meet these criteria. METHODS: We performed a retrospective cohort study, including patients who met current diagnostic criteria for type 1 VHL (Group 1, n = 19) and patients with VHL-associated manifestations that did not meet these criteria (Group 2, n = 21). Genomic DNA was extracted from peripheral blood leukocytes. Mutation analysis involved DNA sequencing, while large deletions were determined by universal primer quantitative fluorescent multiplex polymerase chain reaction (UPQFM-PCR) and multiplex ligation-dependent probe amplification (MLPA) analysis. RESULTS: VHL mutations were detected in 16/19 (84.2%) patients in Group 1 and included: gross deletions (4/16); nonsense mutations (6/16); frameshift mutations (4/16); missense mutations (1/16); and splicing mutations (1/16). Three of these mutations were novel. No alterations were found in 3 of 19 VHL patients. In Group 2, one nonsense VHL mutation was detected in a young patient with a solitary central nervous system hemangioblastoma without familial history. A study of 30 first-degree relatives revealed four carriers with VHL mutations. CONCLUSIONS: We found three novel mutations in the VHL gene in our population. Our results emphasize the importance of a complete genetic study of VHL to confirm type 1 VHL disease, not only in patients with clinical diagnostic criteria but also in those presenting a single typical manifestation.
Sujet(s)
Mutation germinale , Protéine Von Hippel-Lindau supresseur de tumeur/génétique , Maladie de von Hippel-Lindau/génétique , Adolescent , Adulte , Sujet âgé , Argentine , Asiatiques/génétique , Enfant , Enfant d'âge préscolaire , Codon non-sens/génétique , Études de cohortes , Analyse de mutations d'ADN , Femelle , Mutation avec décalage du cadre de lecture/génétique , Hémangioblastome/génétique , Humains , Mâle , Adulte d'âge moyen , Réaction de polymérisation en chaine multiplex , Mutation faux-sens/génétique , Pedigree , Études rétrospectives , Délétion de séquence , Protéine Von Hippel-Lindau supresseur de tumeur/sang , Protéine Von Hippel-Lindau supresseur de tumeur/métabolismeRÉSUMÉ
Los eventos tromboembólicos cerebrales están asociados con secuelas permanentes y con deterioro de la calidad de vida. Sangrados, trastornos venosos y arteriales han sido descriptos con el uso de agentes antiangiogénicos. Presentamos un caso con sarcoma mixoide que desarrolló un accidente cerebrovascular isquémico mientras estaba siendo tratado con sorafenib. Repasamos también las drogas usadas en oncología que podrían estar asociadas con eventos tromboembólicos arteriales o venosos. Los médicos tratantes deberían monitorear a los pacientes que reciben agentes antiangiogénicos en relación a síntomas neurológicos y, en ausencia de otras etiologías, la pronta suspensión de la droga debería ser considerada (AU)
The cerebral thromboembolic events are linked with permanent sequelae and deterioration in quality of life. Bleeding, venous and arterial thromboembolic events have been described with antiangiogenics agents. We report a case with myxoid sarcoma that developed a cerebrovascular accident while on sorafenib treatment. We also reviewed drugs used in oncology that could be associated with arterial and venous thromboembolic events. Physicians should monitor patients receiving antiangiogenics agents for neurologic symptoms and in the absences of other etiology, prompt discontinuation of these drugs should be considered (AU)
Sujet(s)
Humains , Mâle , Sujet âgé , Inhibiteurs de l'angiogenèse/usage thérapeutique , Angiopathies intracrâniennes , Accident ischémique transitoire/étiologie , Inhibiteurs de l'angiogenèse/effets indésirables , Accident vasculaire cérébral , Facteurs de croissance endothéliale vasculaireRÉSUMÉ
OBJECTIVES: To evaluate patterns of relapse and outcome in patients newly diagnosed with CNS Mixed Malignant GCT (MMGCT) treated initially with chemotherapy alone. METHODS: A retrospective chart review was conducted using all 25 patients enrolled on the International CNS GCT Study III, with at least 7 years follow-up for all surviving patients. RESULTS: Thirteen patients at diagnosis had CNS MMGCT by pathology and tumor markers (n = 11), or tumor markers alone (n = 2). Twelve received chemotherapy alone, one additionally receiving focal irradiation prior to relapse. Six patients (46%) relapsed (mean of 30.5 months; range 6-59 months), two beyond and four within the primary site alone. Three patients relapsed early (6-23 months from diagnosis), two with alpha-fetoprotein elevations and one without tumor markers assessed; all three expired of progressive disease at 2-10 months following initial relapse. Three patients relapsed late (37-59 months) without AFP elevations, one with pathologically pure germinoma, two with mild beta-human chorionic gonadotropin elevations; these patients survive disease-free at 86+, 94+, and 126+ months following additional treatment. CONCLUSIONS: Patients with CNS MMGCT relapsing following chemotherapy alone display two distinct patterns of recurrence and outcome; patients relapsing early possess MMGCT elements and have a dismal prognosis, while patients relapsing late do so with pure germinomatous elements and have an excellent outcome. Current cooperative group studies utilizing more localized fields of irradiation should monitor closely the patterns of relapse and outcome; late recurrences with germinomatous elements might be avoided by initial use of low-dose larger field irradiation in select patients.
Sujet(s)
Tumeurs du système nerveux central/mortalité , Tumeurs embryonnaires et germinales/mortalité , Adolescent , Tumeurs du système nerveux central/thérapie , Enfant , Enfant d'âge préscolaire , Essais cliniques de phase III comme sujet , Survie sans rechute , Femelle , Études de suivi , Humains , Nourrisson , Mâle , Tumeurs embryonnaires et germinales/thérapie , Récidive , Études rétrospectives , Taux de survieRÉSUMÉ
In Rosai-Dorfman disease (RDD), exclusive extranodal involvement with lesions limited to the kidneys is very uncommon and has been described only in adult patients. Occasionally, human herpesvirus 6 (HHV-6) has also been detected in RDD tissue samples. We present the case of a 7-year-old boy referred to our center presenting a single solid mass in the right kidney measuring 3.4 cm, detected both on contrast computed tomography and magnetic resonance imaging. Surgical excision was successfully completed, and the pathology report informed characteristic histopathology and immmunohistochemistry features of RDD. Human herpesvirus 6 was detected and amplified by polymerase chain reaction, as well as by immunohistochemistry. We discuss imaging and histology-based differential diagnoses in the pediatric age group. Although RDD is a rare histiocytic disorder of unknown etiology and pathogenesis, the presence of HHV-6 observed in this case supports the possibility of an abnormal immunologic response linked to viral presence.
Sujet(s)
Herpèsvirus humain de type 6/isolement et purification , Histiocytose sinusale cytophagique/diagnostic , Maladies du rein/diagnostic , Infections à roséolovirus/diagnostic , Enfant , ADN viral/analyse , Diagnostic différentiel , Herpèsvirus humain de type 6/génétique , Histiocytose sinusale cytophagique/chirurgie , Histiocytose sinusale cytophagique/virologie , Humains , Immunohistochimie , Rein/imagerie diagnostique , Rein/anatomopathologie , Maladies du rein/chirurgie , Maladies du rein/virologie , Imagerie par résonance magnétique , Mâle , Réaction de polymérisation en chaîne , Infections à roséolovirus/chirurgie , Infections à roséolovirus/virologie , Tomodensitométrie , Résultat thérapeutiqueRÉSUMÉ
INTRODUCTION: Information about pediatric survivors of brain tumors in developing countries is scant. PURPOSE: In this study, we aimed to investigate the availability of resources for treatment and long-term follow-up of children with central nervous system tumors in developing countries. MATERIALS AND METHODS: A web-based questionnaire on available services and follow-up of brain tumor survivors was posted at www.cure4kids.org , and registered users were invited to participate. RESULTS: A total of 140 evaluable responses from developing countries (n = 103) and high-income countries (n = 37) were obtained. There was a significant correlation between gross national income and the availability of services for treatment and follow-up and between patient load and the availability of some services. CONCLUSION: The resources for treatment and long-term follow-up of children with brain tumors need to be improved in developing countries.
Sujet(s)
Tumeurs du cerveau/thérapie , Prestations des soins de santé/statistiques et données numériques , Pays en voie de développement/statistiques et données numériques , Ressources en santé/statistiques et données numériques , Oncologie médicale , Enfant , Collecte de données , Études de suivi , Humains , Internet , Oncologie médicale/organisation et administration , Temps , EffectifRÉSUMÉ
Objetivo: realizar una evaluación retrospectiva respecto de la correlación entre la técnica de perfusión (PWI) por resonancia magnética (RM), el volumen sanguíneo cerebral relativo (VSCr) y el genotipo tumoral, en pacientes con neoplasias oligodendrogliales grado II. Materiales y métodos: once pacientes (7 hombres y 4 mujeres), con un rango de edad entre los 28 y 64 años, con tumores oligodendrogliales (OD) grado II, fueron estudiados con RM convencional y PWI, con la finalidad de obtener un valor de VSCr. Se realizó el análisis genético en todos los pacientes para evaluar el estado de los cromosomas 1p/19q. Resultados: cinco pacientes con tumores ODs grado II (45%) presentaron un VSCr < 1,75 y ausencia de alteraciones en 1p/19q. Tres pacientes tenían oligoastrocitomas (OA), 2 de ellos con alteraciones en 1p/19q y el restante con 1p/19q intacto. Dos de los pacientes con gliomas mixtos, uno con alteración en 1p/19q y el otro con 1p/19q intacto, presentaron un VSCr> 1,75, mientras que en el paciente restante con glioma mixto y deleción en 1p/19q, el VSCr fue de < 1,75. Dos pacientes con ODs grado II presentaron un VSCr> 1,75, uno con 1p/19q intacto y el restante con deleción en 1p/19q. El último paciente presentó un OD grado II con un VSCr< 1,75 y pérdida de 1p/19q. Conclusiones: aproximadamente el 45% de los pacientes con los cromosomas 1p/19q intactos mostró un VSCr< 1,75, lo que sugiere una neoangiogénesis tumoral limitada. Estos hallazgos podrían ser de utilidad para monitorear respuesta a agentes antiangiogénicos. Los estudios realizados en series mayores podrían proporcionar información valiosa antes de la cirugía y contribuir a un mejor manejo de estos pacientes.
Objective: To perform a retrospective assessment of the correlation between perfusion MR imaging, relative cerebral blood volume (rCBV) and genotype in patients with grade II oligodendroglial neoplasms. Materials and methods: Eleven patients (7 men and 4 women), age range: 28-64 years, with grade II oligodendroglial tumors (OD) were studied using conventional MR and perfusion MR imaging (rCBV). Genetic analysis was carried out in all patients to assess -1p/-19q genotype status. Results: Five patients with grade II oligodendroglial tumors (45%) presented rCBV < 1.75 and intact 1p/19q. Three patients had mixed gliomas, two of them had deletion in 1p/19q, and the other presented intact 1p/19 q. rCBV was > 1.75 in two patients and < 1.75 in the other patient. Two patients with grade II oligodendroglioma had an rCBV > 1.75, one with intact 1p/19q, and the other with deletion. The last patient presented a grade II oligodendroglial tumor with rCBV < 1.75 and 1p/19q loss. Conclusions: Approximately 45% of patients with intact 1p/19q showed rCBV < 1.75, suggesting limited tumor neoangiogenesis. These findings could be important for the antiangiogenic therapy follow-up. Studies in larger series could provide valuable information prior to surgery and contribute to a better management of these patients.
RÉSUMÉ
BACKGROUND: The treatment of central nervous system (CNS) germ cell tumors (GCT) remains controversial. The purpose of this study was to demonstrate efficacy of a chemotherapy only strategy, with less morbidity, when compared to regimens with irradiation. METHODS: Between January 2001 and December 2004 newly diagnosed patients with CNS GCT were treated with one of two risk-tailored chemotherapy regimens. Twenty-five patients aged 4 months to 24.5 years were stratified: Regimen A consisted of 4-6 cycles of carboplatin/etoposide alternating with cyclophosphamide/etoposide for low risk (LR) localized germinoma with normal cerebrospinal fluid (CSF) and serum tumor markers. Regimen B consisted of 4-6 cycles of carboplatin/cyclophosphamide/etoposide for intermediate-risk (IR) germinoma with positive human chorionic gonadotrophin-beta (HCGbeta) and/or CSF HCGbeta <50 mIU/ml and high-risk (HR) biopsy-proven non-germinomatous malignant elements (MMGCT) or elevated serum/CSF alpha-fetoprotein and/or HCGbeta serum/CSF >50 mIU/ml. RESULTS: Eleven patients were classified as LR, 2 IR, and 12 HR. Seventeen (68%) patients achieved complete radiographic and marker responses after two courses and 19 (76%) after four courses of chemotherapy. Eleven patients relapsed at a mean of 30.8 months; eight of them subsequently received irradiation. The 6-year event free and overall survival for the 25 patients was 45.6% and 75.3%, respectively. CONCLUSION: These intensive chemotherapy regimens proved less effective than irradiation containing regimens. Our results indicate that, at the present time, standard treatment for CNS GCT continues to include irradiation either alone or combined with chemotherapy for pure germinomas and with chemotherapy for those with MMGCT.
Sujet(s)
Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Tumeurs du cerveau/traitement médicamenteux , Tumeurs embryonnaires et germinales/traitement médicamenteux , Adolescent , Adulte , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Tumeurs du cerveau/anatomopathologie , Tumeurs du cerveau/radiothérapie , Tumeurs du cerveau/chirurgie , Carboplatine/administration et posologie , Carboplatine/effets indésirables , Enfant , Enfant d'âge préscolaire , Association thérapeutique , Cyclophosphamide/administration et posologie , Cyclophosphamide/effets indésirables , Étoposide/administration et posologie , Étoposide/effets indésirables , Femelle , Humains , Nourrisson , Mâle , Tumeurs embryonnaires et germinales/anatomopathologie , Tumeurs embryonnaires et germinales/radiothérapie , Tumeurs embryonnaires et germinales/chirurgie , Résultat thérapeutique , Jeune adulteRÉSUMÉ
PURPOSE: Oral temozolomide is approved in many countries for malignant glioma and for melanoma in some countries outside the USA. This study evaluated the exposure equivalence and safety of temozolomide by intravenous infusion and oral administration. METHODS: Subjects with primary central nervous system malignancies (excluding central nervous system lymphoma) received 200 mg/m(2) of oral temozolomide on days 1, 2 and 5. On days 3 and 4, subjects received 150 mg/m(2) temozolomide either as a 90-min intravenous infusion on one day or by oral administration on an alternate day. RESULTS: Ratio of log-transformed means (intravenous:oral) of area under the concentration-time curve and maximum concentration of drug after dosing for temozolomide and 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC) met exposure equivalence criteria (90% confidence interval = 0.8-1.25). Treatment-emergent adverse events were consistent with those reported previously in subjects with recurrent glioma treated with oral temozolomide, except for mostly mild and transient injection site reactions with intravenous administration. CONCLUSIONS: This study demonstrated an exposure equivalence of a 90-min intravenous infusion of temozolomide and an equivalent oral dose.
Sujet(s)
Tumeurs du système nerveux central/traitement médicamenteux , Dacarbazine/analogues et dérivés , Administration par voie orale , Adulte , Anémie/induit chimiquement , Antinéoplasiques alcoylants/administration et posologie , Antinéoplasiques alcoylants/effets indésirables , Antinéoplasiques alcoylants/pharmacocinétique , Aire sous la courbe , Tumeurs du système nerveux central/métabolisme , Constipation/induit chimiquement , Études croisées , Dacarbazine/administration et posologie , Dacarbazine/pharmacocinétique , Calendrier d'administration des médicaments , Femelle , Céphalée/induit chimiquement , Humains , Perfusions veineuses , Mâle , Taux de clairance métabolique , Adulte d'âge moyen , Nausée/induit chimiquement , Témozolomide , Équivalence thérapeutique , Facteurs temps , Vomissement/induit chimiquementRÉSUMÉ
Atypical choroid plexus papilloma (APP) represents a novel intermediate-grade subtype of choroid plexus tumor (CPT), the clinical outcome of which has not been described yet. We present the first analysis of a group of APP patients enrolled in the ongoing CPT-SIOP-2000 study of CPTs. A worldwide registration and a randomized trial for those patients who require chemotherapy started in 2000. For APP, maximal surgical resection was recommended. After surgery, patients who had undergone complete resection were observed, whereas patients with incompletely resected or metastasized APP were treated with six chemotherapy courses (etoposide and vincristine, combined with either carboplatin or cyclophosphamide). Risk-adapted radiotherapy was given only to patients older than 3 years of age. Of the 106 patients with a centrally confirmed CPT histology, 30 had APP, 42 CPP and 34 CPC. APP patients were significantly younger (median = 0.7 years) than patients with CPP or CPC (both medians = 2.3 years). Complete resection was achieved in 68 (64%) patients (79% in CPP, 63% in APP, and 47% in CPC). Metastases were present at diagnosis in 17% of APP patients, 5% of CPP patients, and 21% of CPC patients. All nine APP patients who received postoperative chemotherapy showed an early response after two cycles: two had complete remission, four had partial response, and three had stable disease. In the observation group of 15 patients, one event was seen, and all patients were alive. In the treatment group, one patient with a metastasized tumor and incompletely resected APP died. While APP was defined histologically, median percentages of both the Ki-67/MIB-1 proliferation marker and the p53 tumor suppressor protein increased across the three histological subtypes (from CPP to APP and then CPC), suggesting that the subtypes comprise an ordinal categorization of increasingly severe CPT tumors. This ordering was reiterated by clinical outcome in the 92 patients treated per the study protocol, with 5-year EFS rates of 92% in 39 CPP patients, 83% in 24 APP patients, and 28% in 29 CPC patients. A similar ordering was seen when all 106 patients were evaluated for EFS. APP responded favorably to chemotherapy. The intermediate position of APP between CPP and CPC was supported by the clinical data.
Sujet(s)
Protocoles de polychimiothérapie antinéoplasique/administration et posologie , Tumeurs du plexus choroïde/traitement médicamenteux , Tumeurs du plexus choroïde/mortalité , Papillome du plexus choroïde/traitement médicamenteux , Papillome du plexus choroïde/mortalité , Adolescent , Adulte , Carboplatine/administration et posologie , Enfant d'âge préscolaire , Tumeurs du plexus choroïde/anatomopathologie , Association thérapeutique , Cyclophosphamide/administration et posologie , Étoposide/administration et posologie , Femelle , Gadolinium , Humains , Nourrisson , Estimation de Kaplan-Meier , Imagerie par résonance magnétique , Mâle , Adulte d'âge moyen , Papillome du plexus choroïde/anatomopathologie , Enregistrements , Vincristine/administration et posologie , Jeune adulteRÉSUMÉ
BACKGROUND: To determine the impact of diagnostic serum and/or cerebrospinal fluid (CSF) alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin (b-HCG) elevations on survival in newly diagnosed patients with central nervous system germ cell tumors (CNS GCT) treated with chemotherapy with the intent to avoid irradiation. PROCEDURE: Seventy-five patients with newly diagnosed CNS GCT enrolled in two sequential internationally conducted clinical trials with serum and CSF AFP and b-HCG levels available from initial diagnosis were retrospectively analyzed. Subjects received platinum based chemotherapy and were followed with serial imaging and tumor marker evaluations. RESULTS: The 5-year overall survival (OS) and event free survival (EFS) for patients with normal tumor markers compared with those with elevated markers at diagnosis was 78% (95% CI 51-91%) versus 60% (95% CI 46-72%) (P = 0.08) and 22% (95% CI 7-43%) versus 28% (95% CI 16-40%) (P = 0.68). The hazard ratio of death for patients with elevated markers was 1.9 times as high as that for those with normal markers (95% CI 0.58-6.5) after adjusting for other baseline characteristics. There was no observed difference in survival among patients with histologically confirmed germinomas, irrespective of level of b-HCG. CONCLUSIONS: Patients with elevated tumor markers appear to have poorer OS independent of tumor histology, although these differences do not reach statistical significance (P < or = 0.05). No differences were observed in EFS between groups likely due to the poor response of chemotherapy only approach to patients with normal markers. b-HCG elevations in biopsy proven germinomas do not seem to alter a patient's prognosis.
Sujet(s)
Marqueurs biologiques tumoraux/sang , Marqueurs biologiques tumoraux/liquide cérébrospinal , Tumeurs du cerveau/mortalité , Tumeurs embryonnaires et germinales/mortalité , Adolescent , Tumeurs du cerveau/sang , Tumeurs du cerveau/liquide cérébrospinal , Enfant , Sous-unité bêta de la gonadotrophine chorionique humaine/sang , Sous-unité bêta de la gonadotrophine chorionique humaine/liquide cérébrospinal , Survie sans rechute , Femelle , Humains , Mâle , Stadification tumorale , Tumeurs embryonnaires et germinales/sang , Tumeurs embryonnaires et germinales/liquide cérébrospinal , Pronostic , Études rétrospectives , Taux de survie , Résultat thérapeutique , Alphafoetoprotéines/analyse , Alphafoetoprotéines/liquide cérébrospinalRÉSUMÉ
PURPOSE: To determine the survival of infants and young children with non-metastatic medulloblastoma using intensive myeloablative chemotherapy and autologous hematopoietic progenitor cell rescue (AuHCR). METHODS: Twenty-one children less than 3 years old at diagnosis with non-metastatic medulloblastoma were enrolled on two identical serial studies, "Head Start" I and "Head Start" II. After surgery, patients received five cycles of induction chemotherapy consisting of vincristine, cisplatin, cyclophosphamide and etoposide. Following induction, all patients underwent myeloablative chemotherapy using carboplatin, thiotepa and etoposide with AuHCR. Irradiation was used only at relapse. RESULTS: The 5-year event-free (EFS) and overall survival (OS) rates (+/-SE) for all patients, patients with gross total resection, and patients with residual tumor were 52 +/- 11% and 70 +/- 10%, 64 +/- 13% and 79 +/- 11%, and 29 +/- 17% and 57 +/- 19%, respectively. The 5-year EFS and OS ( +/- SE) for patients with desmoplastic and classical medulloblastoma were 67 +/- 16% and 78 +/- 14%, and 42 +/- 14 and 67 +/- 14%, respectively. There were four treatment related deaths. The majority of survivors (71%) avoided irradiation completely. Mean intellectual functioning and quality of life (QoL) for children surviving without irradiation was within average range for a majority of survivors tested. CONCLUSION: This strategy of brief intensive chemotherapy for young children with non-metastatic medulloblastoma eliminated the need for craniospinal irradiation 52% of the patients, and may preserve QoL and intellectual functioning. The excellent survival rates are somewhat dampened by high toxic mortality.
Sujet(s)
Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Tumeurs du cervelet/traitement médicamenteux , Médulloblastome/traitement médicamenteux , Tumeurs du cervelet/mortalité , Tumeurs du cervelet/chirurgie , Comportement de l'enfant , Enfant d'âge préscolaire , Association thérapeutique , Survie sans rechute , Femelle , Humains , Nourrisson , Tests d'intelligence , Mâle , Médulloblastome/mortalité , Médulloblastome/chirurgie , Tests neuropsychologiques , Qualité de vie , Taux de survieRÉSUMÉ
BACKGROUND: Children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNET) have poor outcomes compared to medulloblastoma patients, despite similar treatments. In an effort to improve overall survival (OS) and event-free survival (EFS) and to decrease radiation exposure, the Head Start (HS) protocols treated children with newly diagnosed sPNET utilizing intensified induction chemotherapy (ICHT) followed by consolidation with myeloablative chemotherapy and autologous hematopoietic cell rescue (AuHCR). PROCEDURES: Between 1991 and 2002, 43 children with sPNET were prospectively treated on two serial studies (HS I and II). After maximal safe surgical resection, patients on HS I and patients with localized disease on HS II were treated with five cycles of ICHT (vincristine, cisplatin, cyclophosphamide, and etoposide). Patients on HS II with disseminated disease received high-dose methotrexate during ICHT. If the disease remained stable or in response, patients received a single cycle of high-dose myeloablative chemotherapy followed by AuHCR. RESULTS: Five-year EFS and OS were 39% (95%CI: 24%, 53%) and 49 (95%CI: 33%, 62%), respectively. Non-pineal sPNET patients faired significantly better than those patients with pineal sPNETs. Metastasis at diagnosis, age, and extent of resection were not significant prognostic factors. Sixty percent of survivors (12 of 20) are alive without exposure to radiation therapy. CONCLUSIONS: ICHT followed by AuHCR in young patients with newly diagnosed sPNET appears to not only provide an improved EFS and OS for patients who typically have a poor prognosis, but also it successfully permitted deferral and elimination of radiation therapy in a significant proportion of patients.
Sujet(s)
Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Transplantation de cellules souches hématopoïétiques , Tumeurs neuroectodermiques primitives/thérapie , Tumeurs sus-tentorielles/thérapie , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Carboplatine/administration et posologie , Enfant d'âge préscolaire , Cisplatine/administration et posologie , Association thérapeutique , Cyclophosphamide/administration et posologie , Survie sans rechute , Étoposide/administration et posologie , Femelle , Facteur de stimulation des colonies de granulocytes/administration et posologie , Humains , Mâle , Mesna/administration et posologie , Méthotrexate/administration et posologie , Tumeurs neuroectodermiques primitives/traitement médicamenteux , Tumeurs neuroectodermiques primitives/radiothérapie , Tumeurs neuroectodermiques primitives/chirurgie , Tumeurs sus-tentorielles/traitement médicamenteux , Tumeurs sus-tentorielles/radiothérapie , Tumeurs sus-tentorielles/chirurgie , Taux de survie , Vincristine/administration et posologieRÉSUMÉ
Objective: To show implementation and development of an operating room in which we operated 83 patients using intraoperative MRI (REMAIN). Method: We used a side-opening-magnet, 0.23 Tesla, installed in a surgical area specially designed with all the advances of the modern operating rooms. Results: A great variety of neuro-surgical procedures can be made with REMAIN controls. The obtained images are clear, without devices and with an excellent definition of the anatomical structures and the pathology, that allows the neurosurgeon to make more precise and safer interventions. Conclusions: The images of REMAIN in a surgical scope, make possible that injuries can be identified and located with absolute precision. It is particularly useful in determining with exactitude the tumor-like limits, optimizing the surgical approaches, obtaining complete extirpations of brain injuries and controlling the possible intraoperative complications.